{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:40:15Z","timestamp":1787010015682,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To assess the impact of disease activity on clinical outcomes in a \u201creal-world\u201d cohort with neovascular age-related macular degeneration over 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were obtained from the prospectively defined Fight Retinal Blindness! registry. Eyes were divided into tertiles based on the proportion of visits where choroidal neovascular lesion was active (low, moderate, and high) up until 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Data from 2,109 eyes were included. The adjusted mean (95% confidence interval) visual acuity change was \u22120.5 letters (\u22121.8 to 1.1), 1.8 letters (0.2 to 3.4), and \u22122.5 letters (\u22124.2 to \u22121.3) in the low, moderate, and high activity groups respectively,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001. Eyes in the low activity group were more likely to develop macular atrophy (56, 47 and 26% in the low, moderate, and high activity groups respectively,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) but less likely to develop subretinal fibrosis (27, 35 and 42% in the low, moderate, and high activity groups respectively,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Eyes with higher and lower levels of disease activity had poorer outcomes than eyes with moderate activity over 5 years, apparently because of the development of subretinal fibrosis or macular atrophy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000003267","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T09:03:58Z","timestamp":1626944638000},"page":"95-106","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["THE IMPACT OF DISEASE ACTIVITY ON 5-YEAR OUTCOMES IN PATIENTS UNDERGOING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-7081","authenticated-orcid":false,"given":"Kelvin Yi","family":"Chong Teo","sequence":"first","affiliation":[{"name":"Medical Retina Department, Singapore Eye Research Institute, Singapore National Eye Centre, Singapore;"},{"name":"Duke-NUS Medical School, National University of Singapore, Singapore;"},{"name":"The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Ming","family":"Gemmy Cheung","sequence":"additional","affiliation":[{"name":"Medical Retina Department, Singapore Eye Research Institute, Singapore National Eye Centre, Singapore;"},{"name":"Duke-NUS Medical School, National University of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Marsden Eye Specialists, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred K.","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre for Ophthalmology and Visual Science (Incorporating Lions Eye Institute), the University of Western Australia, Perth, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, Sydney, Australia;"},{"name":"University Hospital Zurich and University of Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Gillies","sequence":"additional","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2019.02.005","article-title":"Randomized trial of treat and extend ranibizumab with and without navigated laser versus monthly dosing for diabetic macular edema: TREX-DME 2-year outcomes","volume":"202","author":"Payne","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","article-title":"Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project","volume":"34","author":"Gillies","year":"2014","journal-title":"Retina"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/bjophthalmol-2014-305514","article-title":"Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data","volume":"99","author":"Barthelmes","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","article-title":"Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service","volume":"33","author":"Gale","year":"2019","journal-title":"Eye (Lond)"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.oret.2020.03.017","article-title":"Detrimental effect of delayed re-treatment of active disease on outcomes in neovascular age-related macular degeneration: the RAMPS study","volume":"4","author":"Chong Teo","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity","volume":"121","year":"2014","journal-title":"Ophthalmology"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the comparison of age-related macular degeneration treatments trials","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"116.e1","DOI":"10.1016\/j.ajo.2013.02.012","article-title":"Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab","volume":"156","author":"Bloch","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12886-017-0544-x","article-title":"Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab","volume":"17","author":"Gonzalez-Buendia","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.oret.2019.06.002","article-title":"The evolution of fibrosis and atrophy and their relationship with visual outcomes in asian persons with neovascular age-related macular degeneration","volume":"3","author":"Cheung","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/IAE.0000000000002779","article-title":"Prevalence and risk factors for the development of physician-graded subretinal fibrosis in eyes treated for neovascular age-related macular degeneration","volume":"40","author":"Teo","year":"2020","journal-title":"Retina"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/IAE.0b013e3182657fff","article-title":"Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy","volume":"33","author":"Lois","year":"2013","journal-title":"Retina"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","article-title":"The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration\u2014a phase IV randomised clinical trial with ranibizumab: the FLUID study","volume":"16","author":"Arnold","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/IAE.0b013e31820d3f3f","article-title":"Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy","volume":"31","author":"Lai","year":"2011","journal-title":"Retina"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/bjophthalmol-2019-315055","article-title":"Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project","volume":"104","author":"Daien","year":"2019","journal-title":"Br J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T14:07:15Z","timestamp":1749305235000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003267","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}